Loading…
Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2017
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
94pct
292d open
vs 7,393 other HR bills in the 115th — cohort avg 50d
(This measure has not been amended since it was introduced. The expanded summary of the House reported version is repeated here.) Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2017 (Sec. 2) This bill amends the Public Health Service Act to authorize the Department of Health and Human Services to make grants to states to: (1) collect data on the prevalence and distribution of sickle cell disease, (2) conduct sickle cell disease public health initiatives to improve access to care and health outcomes, and (3) identify and evaluate strategies for prevention and treatment of sickle cell disease complications. (Sec. 4) The demonstration program to improve the prevention and treatment of sickle cell disease is revised, reauthorized through FY2022, and moved from the American Jobs Creation Act of 2004 to the Public Health Service Act.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (8)
Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Motion to reconsider laid on the table Agreed to without objection.
On motion to suspend the rules and pass the bill Agreed to by voice vote. (text: CR H1240-1241)
Passed/agreed to in House: On motion to suspend the rules and pass the bill Agreed to by voice vote.(text: CR H1240-1241)
DEBATE - The House proceeded with forty minutes of debate on H.R. 2410.
Considered under suspension of the rules. (consideration: CR H1240-1243)
Mr. Burgess moved to suspend the rules and pass the bill.
Placed on the Union Calendar, Calendar No. 258.
Reported by the Committee on Energy and Commerce. H. Rept. 115-354.
Congress.gov source codes: 5000, H12200
Ordered to be Reported by Voice Vote.
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2026 · third_quarter · Taxation/Internal Revenue Code
Monitor implementation of the Tax Cuts and Jobs Act of 2017, specifically section 179 Support the Main Street Tax Certainty Act (H.R. 703/S. 213) Support the continuation of stepped-up basis for capital gains taxes Monitor provisions of the Inflation Reduction Act and implementation Support the Small Business Growth Act (H.R. 354) Support the American Innovation and R&D Competitiveness Act (H.R. 1990) Support the USA Workforce Investment Act (H.R. 5493) Support the Death Tax Repeal Act (H.R. 1301/S. 587) Monitor the implementation of the Freedom to Invest in Tomorrow's Workforce Act (H.R. 1151/S. 756) Support and monitor implementation of the One Big Beautiful Bill Act (H.R. 1) Support the Revitalizing Downtowns and Main Streets Act (H.R. 2410) Support the Neighborhood Homes Investment Act (H.R. 2854/S. 1686) Support the extension of the Workforce Opportunity Tax Credit Support the American Energy Dominance Act (H.R. 8477) Support the S Corporation Modernization Act (H.R. 9480 and S. 2017)
Client expense: $200,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Internal Revenue Service (IRS), SENATE, Small Business Administration (SBA), Treasury, Dept of
2026 · second_quarter · Taxation/Internal Revenue Code
Monitor implementation of the Tax Cuts and Jobs Act of 2017, specifically section 179 Support the Main Street Tax Certainty Act (H.R. 703/S. 213) Support the continuation of stepped-up basis for capital gains taxes Monitor provisions of the Inflation Reduction Act and implementation Support the Small Business Growth Act (H.R. 354) Support the American Innovation and R&D Competitiveness Act (H.R. 1990) Support the USA Workforce Investment Act (H.R. 5493) Support the Death Tax Repeal Act (H.R. 1301/S. 587) Monitor the implementation of the Freedom to Invest in Tomorrow's Workforce Act (H.R. 1151/S. 756) Support and monitor implementation of the One Big Beautiful Bill Act (H.R. 1) Support the Revitalizing Downtowns and Main Streets Act (H.R. 2410) Support the Neighborhood Homes Investment Act (H.R. 2854/S. 1686)
Client expense: $200,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Internal Revenue Service (IRS), SENATE, Small Business Administration (SBA), Treasury, Dept of
2026 · first_quarter · Taxation/Internal Revenue Code
Monitor implementation of the Tax Cuts and Jobs Act of 2017, specifically section 179 Support the Main Street Tax Certainty Act (H.R. 703/S. 213) Support the continuation of stepped-up basis for capital gains taxes Monitor provisions of the Inflation Reduction Act and implementation Support the Small Business Growth Act (H.R. 354) Support the American Innovation and R&D Competitiveness Act (H.R. 1990) Support the USA Workforce Investment Act (H.R. 5493) Support the Death Tax Repeal Act (H.R. 1301/S. 587) Monitor the implementation of the Freedom to Invest in Tomorrow's Workforce Act (H.R. 1151/S. 756) Support and monitor implementation of the One Big Beautiful Bill Act (H.R. 1) Support the Revitalizing Downtowns and Main Streets Act (H.R. 2410) Support the Neighborhood Homes Investment Act (H.R. 2854/S. 1686)
Client expense: $200,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Internal Revenue Service (IRS), SENATE, Small Business Administration (SBA), Treasury, Dept of
2025 · fourth_quarter · Taxation/Internal Revenue Code
Monitor implementation of the Tax Cuts and Jobs Act of 2017, specifically section 179 Support the Main Street Tax Certainty Act (H.R. 703/S. 213) Support the continuation of stepped-up basis for capital gains taxes Monitor provisions of the Inflation Reduction Act and implementation, especially support for sections 179D and 45L Support the Small Business Growth Act (H.R. 354) Support the American Innovation and R&D Competitiveness Act (H.R. 1990) Support the USA Workforce Investment Act (H.R. 5493) Support the Death Tax Repeal Act (H.R. 1301/S. 587) Monitor the implementation of the Freedom to Invest in Tomorrow's Workforce Act (H.R. 1151/S. 756) Support and monitor implementation of the One Big Beautiful Bill Act (H.R. 1) Support the Revitalizing Downtowns and Main Streets Act (H.R. 2410) Support the Neighborhood Homes Investment Act (H.R. 2854/S. 1686)
Client expense: $200,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Internal Revenue Service (IRS), SENATE, Small Business Administration (SBA), Treasury, Dept of
2018 · fourth_quarter · Medical/Disease Research/Clinical Labs
Essential emergency medication shortages H.R.2410-Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2017 H.R.6615-Traumatic Brain Injury Program Reauthorization Act of 2018 H.R.6748-Emergency Medical Services for Children Program Reauthorization Act of 2018 H.R.7223-Right Rebate Act of 2018 S.2465-Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2018 S.3482-Emergency Medical Services for Children Program Reauthorization Act of 2018 S.3657-Traumatic Brain Injury Program Reauthorization Act of 2018 S.3702-Right Rebate Act of 2018
Client expense: $549,617 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
2018 · fourth_quarter · Health Issues
Essential emergency medication shortages Mental health services for emergency psychiatric patients Price transparency, out-of-network reimbursement of emergency medical services H.Res.906-Congratulating the American College of Emergency Physicians on its 50th anniversary H.R.6-Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act H.R.372-Competetive Health Insurance Reform Act of 2017 H.R.548-Health Care Safety Net Enhancement Act of 2017 H.R.767-Stop, Observe, Ask, and Respond (SOAR) to Health and Wellness Act of 2017 H.R.817-End Surprise Billing Act of 2017 H.R.880-Military Injury Surgical Systems Integrated Operationally Nationwide to Achieve ZERO Preventable Deaths Act H.R.1057-Synthetics Trafficking and Overdose Prevention Act of 2017 H.R.1215-Protecting Access to Care Act of 2017 H.R.1323-Reducing Unnecessary Emergency Room Visits under Medicaid Act H.R.1492-Medical Controlled Substances Transportation Act of 2017 H.R.1565-Saving Lives, Saving Costs Act H.R.1822-Good Samaritan Health Professionals Act of 2017 H.R.1876-Good Samaritan Health Professionals Act of 2017 H.R.2200-Frederick Douglass Trafficking Victims Prevention and Protection Reauthorization Act of 2017 H.R.2410-Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2017 H.R.2851-Stop the Importation and Trafficking of Synthetic Analogues (SITSA) Act of 2017 H.R.2957-Save Rural Hospitals Act H.R.3181-Medicare Choices Empowerment and Protection Act H.R.3258-Marketplace Certainty Act H.R.3545-Overdose Prevention and Patient Safety (OPPS) Act H.R.4922-Stopping Overdoses of Fentanyl Analogues Act H.R.5176-Preventing Overdoses While in Emergency Rooms Act of 2018 H.R.5197-Alternatives to Opioids (ALTO) in the Emergency Department Act H.R.5531-Opioid Emergency Response Act H.R.5558-Alternatives to Opioids Prescribing Act H.R.5678-Rural Emergency Medical Center Act of 2018 H.R.5734-Resident Education Deferred Interest Act H.R.6082-Overdose Prevention and Patient Safety (OPPS) Act H.R.6143-Patient Right to Know Drug Prices Act H.R.6144-Know the Lowest Price Act of 2018 H.R.6372-To require the Secretary of Health and Human Services issue regulations to ensure due process rights for physicians furnishing emergency medical services H.R.6502-Reducing Unnecessary Senior Hospitalizations Act of 2018 H.R.6615-Traumatic Brain Injury Program Reauthorization Act of 2018 H.R.6733-Know the Cost Act of 2018 H.R.6748-Emergency Medical Services for Children Program Reauthorization Act of 2018 H.R.7223-Right Rebate Act of 2018 Senate resolution congratulating the American College of Emergency Physicians on its 50th anniversary S.191-Patient Freedom Act of 2017 S.256-SOAR to Health and Wellness Act of 2017 S.284-End Surprise Billing Act of 2017 S.372- Synthetics Trafficking and Overdose Prevention Act of 2017 S.527-Health Care Safety Net Enhancement Act of 2017 S.568-Improving Access to Medicare Coverage Act of 2017 S.781-Good Samaritan Health Professionals Act of 2017 S.1016-Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2017 S.1022-Military Injury Surgical Systems Integrated Operationally Nationwide to Achieve ZERO Preventable Deaths Act S.1130-Rural Emergency Acute Care Hospital (REACH) Act S.1462-Marketplace Certainty Act S.1530- Medicare Choices Empowerment and Protection Act S.1553-Stopping Overdoses of Fentanyl Analogues Act S.1835-Lower Premiums Through Reinsurance Act of 2017 S.2465-Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2018 S.2516-Alternatives to Opioids (ALTO) in the Emergency Department Act S.2544-Patient Right to Know Drug Prices Act S.2553-Know the Lowest Price Act of 2018 S.2609-Recovery Coaches Offer Addiction Counseling and Healing (COACH) Act S.2610-Preventing Overdoses While in Emergency Departments Act of 2018 S.2680-Opioid Crisis Response Act of 2018 S.3482-Emergency Medical Services for Children Program Reauthorization Act of 2018 S.3531-Emergency Care Improvement Act S.3657-Traumatic Brain Injury Program Reauthorization Act of 2018 S.3702-Right Rebate Act of 2018
2018 · third_quarter · Health Issues
Essential emergency medication shortages Mental health services for emergency psychiatric patients Price transparency, out-of-network reimbursement of emergency medical services H.Res.906-Congratulating the American College of Emergency Physicians on its 50th anniversary H.R.6-Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act H.R.372-Competetive Health Insurance Reform Act of 2017 H.R.548-Health Care Safety Net Enhancement Act of 2017 H.R.767-Stop, Observe, Ask, and Respond (SOAR) to Health and Wellness Act of 2017 H.R.817-End Surprise Billing Act of 2017 H.R.880-Military Injury Surgical Systems Integrated Operationally Nationwide to Achieve ZERO Preventable Deaths Act H.R.1057-Synthetics Trafficking and Overdose Prevention Act of 2017 H.R.1215-Protecting Access to Care Act of 2017 H.R.1323-Reducing Unnecessary Emergency Room Visits under Medicaid Act H.R.1492-Medical Controlled Substances Transportation Act of 2017 H.R.1565-Saving Lives, Saving Costs Act H.R.1822-Good Samaritan Health Professionals Act of 2017 H.R.1876-Good Samaritan Health Professionals Act of 2017 H.R.2200-Frederick Douglass Trafficking Victims Prevention and Protection Reauthorization Act of 2017 H.R.2410-Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2017 H.R.2851-Stop the Importation and Trafficking of Synthetic Analogues (SITSA) Act of 2017 H.R.2957-Save Rural Hospitals Act H.R.3181-Medicare Choices Empowerment and Protection Act H.R.3258-Marketplace Certainty Act H.R.3545-Overdose Prevention and Patient Safety (OPPS) Act H.R.4922-Stopping Overdoses of Fentanyl Analogues Act H.R.5176-Preventing Overdoses While in Emergency Rooms Act of 2018 H.R.5197-Alternatives to Opioids (ALTO) in the Emergency Department Act H.R.5531-Opioid Emergency Response Act H.R.5558-Alternatives to Opioids Prescribing Act H.R.5678-Rural Emergency Medical Center Act of 2018 H.R.5734-Resident Education Deferred Interest Act H.R.6082-Overdose Prevention and Patient Safety (OPPS) Act H.R.6143-Patient Right to Know Drug Prices Act H.R.6144-Know the Lowest Price Act of 2018 H.R.6372-To require the Secretary of Health and Human Services issue regulations to ensure due process rights for physicians furnishing emergency medical services H.R.6502-Reducing Unnecessary Senior Hospitalizations Act of 2018 H.R.6733-Know the Cost Act of 2018 Senate resolution congratulating the American College of Emergency Physicians on its 50th anniversary S.191-Patient Freedom Act of 2017 S.256-SOAR to Health and Wellness Act of 2017 S.284-End Surprise Billing Act of 2017 S.372- Synthetics Trafficking and Overdose Prevention Act of 2017 S.527-Health Care Safety Net Enhancement Act of 2017 S.568-Improving Access to Medicare Coverage Act of 2017 S.781-Good Samaritan Health Professionals Act of 2017 S.1016-Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2017 S.1022-Military Injury Surgical Systems Integrated Operationally Nationwide to Achieve ZERO Preventable Deaths Act S.1130-Rural Emergency Acute Care Hospital (REACH) Act S.1462-Marketplace Certainty Act S.1530- Medicare Choices Empowerment and Protection Act S.1553-Stopping Overdoses of Fentanyl Analogues Act S.1835-Lower Premiums Through Reinsurance Act of 2017 S.2465-Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2018 S.2516-Alternatives to Opioids (ALTO) in the Emergency Department Act S.2544-Patient Right to Know Drug Prices Act S.2553-Know the Lowest Price Act of 2018 S.2609-Recovery Coaches Offer Addiction Counseling and Healing (COACH) Act S.2610-Preventing Overdoses While in Emergency Departments Act of 2018 S.2680-Opioid Crisis Response Act of 2018 S.3531-Emergency Care Improvement Act
2018 · third_quarter · Medical/Disease Research/Clinical Labs
Essential emergency medication shortages H.R.2410-Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2017 S.2465-Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2018
Client expense: $402,721 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · fourth_quarter · Medical/Disease Research/Clinical Labs
Research in hematology; legislation to enhance federal efforts on research training and services for sickle cell disease; HR 2410/S 2465 SCD Research, Surveillance Prevention and Treatment Act of 2017
Client expense: Not reported · Firm income: $30,000
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
2018 · fourth_quarter · Medical/Disease Research/Clinical Labs
Sickle cell disease/trait issues Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2017 (H.R. 2410) Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2018/Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2018 (S. 2465) Fetal tissue research Hematology/oncology treatment issues General hematology public health and research issues
Client expense: $30,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
2018 · fourth_quarter · Health Issues
Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2017 (H.R. 2410) Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2018/Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2018 (S. 2465) Cancer Drug Parity Act (H.R. 1409/S. 3742) Patients Access to Treatment Act (H.R. 2999) Implementation of Patient Protection and Affordable Care Act (P.L. 111-148) Repeal of Patient Protection and Affordable Care Act (P.L. 111-148) Hematology and Oncology Drug Research and Approval Issues Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (P.L. 112-144) Clinical trials regulations and coverage Issues impacting coverage for hematologic diseases and conditions Reimbursement for CAR-T and immunotherapies Issues impacting opioid access/use for patients with hematologic diseases and disorders
Client expense: $30,000 · Firm income: Not reported
2018 · fourth_quarter · Health Issues
implementation of health care reform generally pertaining to pediatric health care and autism services Medicaid program reforms, including hospital outpatient department regulations S.3770 (Medicaid Drug Decisions Transparency Act), all provisions Section 340B Drug Pricing Program, including H.R. 4710 (340B PAUSE Act), All provisions, and H.R. 5598 (340B Optimization Act), all provisions and H.R. 6240 (drug Discount accountability act), all provisions Sickle Cell Disease Research funding generally Drug pricing reforms generally Department of Justice implementation of grant program for missing individuals with autism and developmental disabilities Department of Homeland Security rulemaking regarding public charge rule and Medicaid program implications S. 3429 (Neonatal Abstinence Intervention Act), all provisions H.R. 2410 (Sickle Cell Disease research, Surveillance, prevention and treatment act of 2017), all provisions S. 2465 (Sickle cell disease and other heritable blood disorders research, surveillance, Prevention and treatment act of 2018), all provisions H.R. 3325 (ACE kids Act), all provisions S. 428 (Ace Kids Act of 2017), all provisions H.R. 1676 (Palliative Care and Hospice Education and Training Act), all provisions Organ Transplant policy generally, including transplant distribution methodology H.R. 7217 (Improving Medicaid Programs and Opportunities for Eligible Beneficiaries Act - IMPROVE act), Title I, regarding coordinated care
Client expense: $132,091 · Firm income: Not reported
2018 · fourth_quarter · Health Issues
Implementation of health care reform generally pertaining to pediatric health care and autism services Medicaid program reforms, including hospital outpatient department regulations S. 3770 (Medicaid Drug Decisions Transparency Act), all provisions Section 340B Drug Pricing Program, including H.R. 4710 (340B PAUSE Act), all provisions, H.R. 5598 (340B Optimization Act), all provisions, and H.R. 6240 (Drug Discount Accountability Act), all provisions Sickle cell disease research funding generally Drug pricing reforms generally Department of Justice implementation of grant program for missing individuals with autism and developmental disabilities Department of Homeland Security rulemaking regarding public charge rule and Medicaid program implications S. 3429 (Neonatal Abstinence Intervention Act), all provisions H.R. 2410 (Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2017), all provisions S. 2465 (Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2018), all provisions H.R. 3325 (ACE Kids Act), all provisions S. 428 (ACE Kids Act of 2017), all provisions H.R. 1676 (Palliative Care and Hospice Education and Training Act), all provisions Organ transplant policy generally, including liver transplant distribution methodology H.R. 7217 (Improving Medicaid Programs and Opportunities for Eligible Beneficiaries Act - IMPROVE Act), Title I, regarding coordinated care
Client expense: Not reported · Firm income: $50,000
2018 · fourth_quarter · Health Issues
Issues related to drug pricing; issues related to gene editing and gene therapy; H.R. 2410/S. 2465, Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2017; issues related to RMAT designation; issues related to value based arrangements.
Client expense: Not reported · Firm income: $60,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
2018 · third_quarter · Health Issues
implementation of health care reform generally pertaining to pediatric health care and autism services Medicaid program reforms, including hospital outpatient department regulations Section 340B Drug Pricing Program, including H.R. 4710 (340B PAUSE Act), All provisions, and H.R. 5598 (340B Optimization Act), all provisions and H.R. 6240 (drug Discount accountability act), all provisions H.R. 5385 (Dr. Benjy Frances Brooks Children's Hospital GME Support Reauthorization Act of 2018), all provisions S. 2597 (Children's Hospital GME Support Reauthorization act of 2018), all provisions Sickle Cell Disease Research funding generally Drug pricing reforms generally Department of Justice implementation of grant program for missing individuals with autism and developmental disabilities H.R. 6560 (ChiPACC Act of 2018), all provisions Department of Homeland Security rulemaking regarding public charge rule and Medicaid program implications S. 3429 (Neonatal Abstinence Intervention Act), all provisions H.R. 2410 (Sickle Cell Disease research, Surveillance, prevention and treatment act of 2017), all provisions S. 2465 (Sickle cell disease and other heritable blood disorders research, surveillance, Prevention and treatment act of 2018), all provisions H.R. 6 (support for patients and Communities Act), section 1004 regarding Medicaid drug review and utilization H.R. 6458 (National Organ Transplant Act Amendments of 2018), all provisions H.R. 3325 (ACE kids Act), all provisions S. 428 (Ace Kids Act of 2017), all provisions
Client expense: $137,852 · Firm income: Not reported
2018 · third_quarter · Health Issues
Issues related to drug pricing; issues related to gene editing and gene therapy; H.R. 2410/S. 2465, Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2017; issues related to RMAT designation; issues related to value based arrangements.
Client expense: Not reported · Firm income: $60,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
2018 · third_quarter · Health Issues
Implementation of health care reform generally pertaining to pediatric health care and autism services Medicaid program reforms, including hospital outpatient department regulations Section 340B Drug Pricing Program, including H.R. 4710 (340B PAUSE Act), all provisions, H.R. 5598 (340B Optimization Act), all provisions, and H.R. 6240 (Drug Discount Accountability Act), all provisions H.R. 5385 (Dr. Benjy Frances Brooks Children's Hospital GME Support Reauthorization Act of 2018), all provisions S. 2597 (Children's Hospital GME Support Reauthorization Act of 2018), all provisions Sickle cell disease research funding generally Drug pricing reforms generally Department of Justice implementation of grant program for missing individuals with autism and developmental disabilities H.R. 6560 (ChiPACC Act of 2018), all provisions Department of Homeland Security rulemaking regarding public charge rule and Medicaid program implications S. 3429 (Neonatal Abstinence Intervention Act), all provisions H.R. 2410 (Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2017), all provisions S. 2465 (Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2018), all provisions H.R. 6 (SUPPORT for Patients and Communities Act), Section 1004 regarding Medicaid drug review and utilization H.R. 6458 (National Organ Transplant Act Amendments of 2018), all provisions H.R. 3325 (ACE Kids Act), all provisions S. 428 (ACE Kids Act of 2017), all provisions
Client expense: Not reported · Firm income: $50,000
2018 · third_quarter · Health Issues
Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2017 (H.R. 2410) Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2018 (S. 2465) Resolution designating September 2018 as "Sickle Cell Disease Awareness Month" (S.Res. 661) Cancer Drug Parity Act (H.R. 1409) Patients Access to Treatment Act (H.R. 2999) Implementation of Patient Protection and Affordable Care Act (P.L. 111-148) Repeal of Patient Protection and Affordable Care Act (P.L. 111-148) Hematology and Oncology Drug Research and Approval Issues Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (P.L. 112-144) Clinical Trials Regulations and Coverage Issues Impacting Coverage for Hematologic Diseases and Conditions Reimbursement for CAR-T Issues impacting opioid access/use for patients with hematologic diseases and disorders
Client expense: $30,000 · Firm income: Not reported
2018 · third_quarter · Medical/Disease Research/Clinical Labs
Sickle Cell Disease/Trait Issues Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2017 (H.R. 2410) Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2018 (S. 2465) resolution designating September 2018 as "Sickle Cell Disease Awareness Month" (S.Res. 661) Hematology/Oncology Treatment Issues General Hematology Public Health and Research Issues
Client expense: $30,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
2018 · third_quarter · Medical/Disease Research/Clinical Labs
Research in hematology; legislation to enhance federal efforts on research training and services for sickle cell disease; HR 2410/S 2465 SCD Research, Surveillance Prevention and Treatment Act of 2017
Client expense: Not reported · Firm income: $30,000
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
2018 · second_quarter · Medical/Disease Research/Clinical Labs
Sickle Cell Disease/Trait Issues Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2017 (H.R. 2410) Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2018 (S. 2465) Hematology/Oncology Treatment Issues General Hematology Public Health and Research Issues Clinical Trials Regulations Regulation of Laboratory Developed Tests Cancer "Moonshot" Initiative
Client expense: $30,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
2018 · second_quarter · Health Issues
Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2017 (H.R. 2410) Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2018 (S. 2465) Cancer Drug Parity Act (H.R. 1409) Patients Access to Treatment Act (H.R. 2999) Implementation of Patient Protection and Affordable Care Act (P.L. 111-148) Repeal of Patient Protection and Affordable Care Act (P.L. 111-148) Hematology and Oncology Drug Research and Approval Issues Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (P.L. 112-144) Clinical Trials Regulations and Coverage Issues Impacting Coverage for Hematologic Diseases and Conditions Reimbursement for CAR-T Issues impacting opioid access/use for patients with hematologic diseases and disorders
Client expense: $30,000 · Firm income: Not reported
2018 · second_quarter · Health Issues
Issues related to drug pricing; monitored issues related to Right to Try including H.R. 2368 and H.R. 878 and S. 204, Trickett Wendler, Frank Mongiello, Jordan McLinn & Matthew Bellina Right to Try Act of 2017; monitored issues related to gene editing and gene therapy; monitored H.R. 2410/S. 2465, Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2017.
Client expense: Not reported · Firm income: $60,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
2018 · second_quarter · Medical/Disease Research/Clinical Labs
Research in hematology; legislation to enhance federal efforts on research training and services for sickle cell disease; HR 2410/S 2465 SCD Research, Surveillance Prevention and Treatment Act of 2017
Client expense: Not reported · Firm income: $30,000
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
2018 · first_quarter · Health Issues
Issues related to novel therapies for rare pediatric populations; issues related to drug pricing; monitored issues related to Right to Try including H.R. 2368 and H.R. 878 and S. 204, Trickett Wendler, Frank Mongiello, Jordan McLinn & Matthew Bellina Right to Try Act of 2017; monitored issues related to gene editing and gene therapy; monitored H.R. 2410/S. 2465, Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2017.
Client expense: Not reported · Firm income: $60,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
2018 · first_quarter · Medical/Disease Research/Clinical Labs
Research in hematology; legislation to enhance federal efforts on research training and services for sickle cell disease; HR 2410/S 2465 SCD Research, Surveillance Prevention and Treatment Act of 2017
Client expense: Not reported · Firm income: $30,000
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
2018 · first_quarter · Health Issues
Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2017 (H.R. 2410) Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2018 (S. 2465) Cancer Drug Parity Act (H.R. 1409) Patients Access to Treatment Act (H.R. 2999) Implementation of Patient Protection and Affordable Care Act (P.L. 111-148) Repeal of Patient Protection and Affordable Care Act (P.L. 111-148) Hematology and Oncology Drug Research and Approval Issues Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (P.L. 112-144) Clinical Trials Regulations and Coverage Issues Impacting Coverage for Hematologic Diseases and Conditions
Client expense: $30,000 · Firm income: Not reported
2018 · first_quarter · Medical/Disease Research/Clinical Labs
Sickle Cell Disease/Trait Issues Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2017 (H.R. 2410) Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2018 (S. 2465) Hematology/Oncology Treatment Issues General Hematology Public Health and Research Issues Clinical Trials Regulations Regulation of Laboratory Developed Tests Cancer "Moonshot" Initiative Antimicrobial Resistance (AMR) research
Client expense: $30,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
2018 · first_quarter · Health Issues
Sickle Cell Disease Surveillance, Prevention, and Treatment Act of 2018 (H.R. 2410/ S. 2465), which would reauthorize a sickle cell disease prevention and treatment demonstration program and provide for sickle cell disease research, surveillance, prevention, and treatment.
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · first_quarter · Medical/Disease Research/Clinical Labs
Sickle Cell Disease Surveillance, Prevention, and Treatment Act of 2018 (H.R. 2410/ S. 2465), which would reauthorize a sickle cell disease prevention and treatment demonstration program and provide for sickle cell disease research, surveillance, prevention, and treatment.
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · fourth_quarter · Medical/Disease Research/Clinical Labs
Research in hematology; legislation to enhance federal efforts on research training and services for sickle cell disease; HR 2410 SCD Research, Surveillance Prevention and Treatment Act of 2017
Client expense: Not reported · Firm income: $30,000
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
2017 · fourth_quarter · Medical/Disease Research/Clinical Labs
Sickle Cell Disease/Trait Issues Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2017 (H.R. 2410) H.Res. 539, Calling for sickle-cell trait research, surveillance, and public education and awareness Hematology/Oncology Treatment Issues General Hematology Public Health and Research Issues Clinical Trials Regulations Regulation of Laboratory Developed Tests Cancer "Moonshot" Initiative
Client expense: $30,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
2017 · fourth_quarter · Health Issues
Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2017 (H.R. 2410) H.Res. 539, Calling for sickle-cell trait research, surveillance, and public education and awareness S.Res. 27, Designating September 2017 as "Sickle Cell Disease Awareness Month" Cancer Drug Parity Act (H.R. 1409) Patients Access to Treatment Act (H.R. 2999) Implementation of Patient Protection and Affordable Care Act (P.L. 111-148) Repeal of Patient Protection and Affordable Care Act (P.L. 111-148) American Health Care Act/Better Care Reconciliation Act/Health Care Freedom Act (H.R. 1628) Graham-Cassidy-Heller-Johnson Amendment re: ACA repeal/reform Bipartisan Health Care Stabilization Act (proposed by Senators Alexander and Murray) Hematology and Oncology Drug Research and Approval Issues Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (P.L. 112-144) Clinical Trials Regulations and Coverage Issues Impacting Coverage for Hematologic Diseases and Conditions
Client expense: $30,000 · Firm income: Not reported
2017 · third_quarter · Medical/Disease Research/Clinical Labs
Sickle Cell Disease/Trait Issues Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2017 (H.R. 2410) H.Res. 539, Calling for sickle-cell trait research, surveillance, and public education and awareness S.Res.27, Designating September 2017 as "Sickle Cell Disease Awareness Month" Hematology/Oncology Treatment Issues General Hematology Public Health and Research Issues Clinical Trials Regulations Regulation of Laboratory Developed Tests Cancer "Moonshot" Initiative
Client expense: $30,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
2017 · third_quarter · Health Issues
Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2017 (H.R. 2410) H.Res. 539, Calling for sickle-cell trait research, surveillance, and public education and awareness S.Res. 27, Designating September 2017 as "Sickle Cell Disease Awareness Month" Cancer Drug Parity Act (H.R. 1409) Patients Access to Treatment Act (H.R. 2999) Implementation of Patient Protection and Affordable Care Act (P.L. 111-148) Repeal of Patient Protection and Affordable Care Act (P.L. 111-148) American Health Care Act/Better Care Reconciliation Act/Health Care Freedom Act (H.R. 1628) Graham-Cassidy-Heller-Johnson Amendment re: ACA repeal/reform Hematology and Oncology Drug Research and Approval Issues Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (P.L. 112-144) Clinical Trials Regulations and Coverage Issues Impacting Coverage for Hematologic Diseases and Conditions
Client expense: $30,000 · Firm income: Not reported
2017 · third_quarter · Medical/Disease Research/Clinical Labs
Research in hematology; legislation to enhance federal efforts on research training and services for sickle cell disease; HR 2410 SCD Research, Surveillance Prevention and Treatment Act of 2017
Client expense: Not reported · Firm income: $30,000
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
2017 · second_quarter · Health Issues
Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2017 (H.R. 2410) Cancer Drug Parity Act (H.R. 1409) Patients Access to Treatment Act (H.R. 2999) Implementation of Patient Protection and Affordable Care Act (P.L. 111-148) Repeal of Patient Protection and Affordable Care Act (P.L. 111-148) American Health Care Act/Better Care Reconciliation Act (H.R. 1628) Hematology and Oncology Drug Research and Approval Issues Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (P.L. 112-144) Clinical Trials Regulations and Coverage Issues Impacting Coverage for Hematologic Diseases and Conditions
Client expense: $30,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
2017 · second_quarter · Medical/Disease Research/Clinical Labs
Sickle Cell Disease/Trait Issues Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2017 (H.R. 2410) Hematology/Oncology Treatment Issues General Hematology Public Health and Research Issues Clinical Trials Regulations Regulation of Laboratory Developed Tests Cancer "Moonshot" Initiative
Client expense: $30,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
2017 · second_quarter · Medical/Disease Research/Clinical Labs
Research in hematology; legislation to enhance federal efforts on research training and services for sickle cell disease; HR 2410 SCD Research, Surveillance Prevention and Treatment Act of 2017
Client expense: Not reported · Firm income: $30,000
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
Committee Consideration and Mark-up Session Held.
Forwarded by Subcommittee to Full Committee by Voice Vote .
Subcommittee Consideration and Mark-up Session Held.
Referred to the Subcommittee on Health.
Referred to the House Committee on Energy and Commerce.
Introduced in House
Congress.gov source codes: 1000, Intro-H
| House |
| Referred to |
| May 11, 2017 |
| May 11, 2017 |
Client expense: $549,617 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
Client expense: $402,721 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE